Drug Trial Radar · NCT00199368
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,100
Actual
Start
Oct 2004
Primary completion
Mar 2007
Study completion May 2007
Sponsor
- Lead sponsor
- Kyowa Kirin, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Kyowa Hakko Kirin UK, Ltd.
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
Conditions
- Parkinson's Disease
Interventions
Istradefylline ( KW-6002)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kyowa Pharmaceutical Inc.
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.